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EDITORIAL
Imagine a world in which disease management is highly personalised. 
Drug treatments would be specific to the individual concerned, 
taking into account genetic background and environmental factors. 
Therapies would be effective, tailored to the individual’s needs, with 
few or no side-effects. Given that at present many of our treatments 
are based on a one-size-fits-all approach, which clearly has its 
limitations, personalised medicine is an important ideal to pursue. 
The highly publicised notion of precision medicine on the other 
hand aims to identify differences at a population level, guiding the 
application recent technological advances.
Hematopoietic stem cell transplantation (HSCT) is universally 
applied and has been performed successfully for several decades. 
Several new therapies have recently been introduced into the 
clinical arena and many more are on the horizon. Two areas which 
have received a great deal of media attention are chimeric antigen 
receptor T cells (CART cells) and genome editing. The highly 
promising results obtained with CART cells and the implications for 
South African patients have recently been reviewed in the SAMJ by 
Pepper et al.[1] The term genome engineering encompasses a variety 
of techniques which result in alterations of the genome. This can 
be used for research or therapeutic purposes. When applied for 
the latter, it falls within the ambit of gene therapy. This technique 
was recently applied to children born to an HIV-positive father in 
China. The aim was to render the children resistant to HIV. Many 
ethical and scientific questions were raised following the birth of 
these babies, culminating in a call by prominent scientists and 
several organisations to place a moratorium on genome editing 
involving gametes (egg and sperm). 
In this special issue of the SAMJ, the authors have reviewed 
current and imminent cell and gene therapies. Grobbelaar et al.[2] 
review HSCT in South Africa (SA) and highlight limitations to 
its effective and equitable access. Mellet et al.[3] review human 
leukocyte antigen (HLA) diversity and its clinical applications 
in SA, including those related to HSCT, while Wolmarans et 
al.[4] discuss the heterogeneity of cell-therapy products and the 
implications thereof. One of the areas in which important progress 
has been made with gene therapy is primary immune deficiency 
(PID); Erjaee et al.[5] review PID and its treatment on the African 
continent. Ely et al.[6] review the current status of gene and cell 
therapy in SA, while Thomson et al. provide a perspective on the 
South African National Blood Service’s view on cellular therapeutic 
services and products. Exciting new developments in the field of 
gene-modified hematopoietic stem cells (HSCs) are reviewed by 
Alessandrini et al.,[7] while Naidoo et al.[8] provide an overview of 
therapeutic genome modification using neurodegenerative and 
infectious diseases as examples. Fanucci et al.[9] discuss bioprinting 
and its implications for the SA clinical environment. Attention 
is given to specific organ systems by Alessandrini et al.[10] who 
discuss the current status of stem cell therapy for neurological 
disorders, while Niesler et al.[11] review cellular regenerative therapy 
for acquired non-congenital musculoskeletal disorders. The high 
prevalence of HIV in South Africa merits a discussion on the 
effect of the virus on haematopoiesis and in particular on HSCs, 
the quintessential example of adult stem cells; Durandt et al.[12] have 
addressed these issues. 
Finally, Skeen et al.[13] report on an original study conducted 
in SA on people living with spinal cord injuries who received 
‘stem cell therapy’ for their lesions. This study highlights the 
dark side of stem cell therapy, namely stem cell tourism, in which 
emotionally vulnerable patients and their families are exploited, 
both emotionally and financially, and which runs the risk of 
discrediting the cell and gene therapy fields.
An exciting future awaits us as cell and gene therapies come to 
the fore. Impressive results have bene obtained with CART cells 
and haematological malignancies, and with gene therapy for genetic 
disorders (haemophilia, PID). Gene therapy for diseases that are 
highly prevalent on the African continent are imminent: infectious 
diseases (HIV) and haemoglobinopathies (sickle cell disease and 
thalassaemia) being good examples. It is hoped that this special 
edition will provide readers of the SAMJ with insight into these 
rapidly evolving fields and the implications for our patients.
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